In a new clinical trial, people with obesity and knee osteoarthritis who took an experimental drug from Eli Lilly lost large amounts of weight—nearly a third of their body weight in just over a year.
Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results